

Kai P Huang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8015814/publications.pdf>

Version: 2024-02-01

17
papers

224
citations

1478505

6
h-index

996975

15
g-index

18
all docs

18
docs citations

18
times ranked

446
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [177Lu]Lu-DOTATOC. <i>Cancers</i> , 2022, 14, 1768.	3.7	2
2	Correlation Between Quantitative PSMA PET Parameters and Clinical Risk Factors in Non-Metastatic Primary Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, 879089.	2.8	2
3	Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT. <i>Pharmaceutics</i> , 2022, 14, 1278.	4.5	7
4	The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. <i>Cancers</i> , 2021, 13, 635.	3.7	10
5	In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2nd Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With 177Lu-PSMA. <i>Frontiers in Oncology</i> , 2021, 11, 578093.	2.8	18
6	Sentinel Lymph Node Biopsy in Early Stages of Oral Squamous Cell Carcinoma Using the Receptor-Targeted Radiotracer 99mTc-Tilmanocept. <i>Diagnostics</i> , 2021, 11, 1231.	2.6	7
7	Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen. <i>Annals of Nuclear Medicine</i> , 2021, 35, 314-320.	2.2	6
8	Shortened Tracer Uptake Time in GA-68-DOTATOC-PET of Meningiomas Does Not Impair Diagnostic Accuracy and PET Volume Definition. <i>Diagnostics</i> , 2020, 10, 1084.	2.6	3
9	Relationship of Renal Function in Mice to Strain, Sex and 177Lutetium-Somatostatin Receptor Ligand Treatment. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 381-386.	0.7	1
10	18F-sodium fluoride bone deposition quantitation with PET in Mice: Variation with age, sex, and circadian rhythm. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 428-437.	0.7	0
11	Normal Values for Parotid Gland and Submandibular-Sublingual Salivary Gland Complex Uptake of 99mTechnetium Perchnetate using SPECT in Mice with Respect to Age, Sex, and Circadian Rhythm. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, 39-49.	0.7	1
12	Prostate-Specific Membrane Antigen-Positive Manifestations of Chronic Beryllium Lung Disease. <i>Clinical Nuclear Medicine</i> , 2019, 44, 64-65.	1.3	3
13	Tumor Lysis Syndrome: A Rare but Serious Complication of Radioligand Therapies. <i>Journal of Nuclear Medicine</i> , 2019, 60, 752-755.	5.0	17
14	Immunohistochemical Validation of PSMA Expression Measured by ⁶⁸ Ga-PSMA PET/CT in Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 238-243.	5.0	120
15	Normal Values of Renal Function measured with 99mTechnetium Mercaptoacetyltriglycine SPECT in Mice with Respect to Age, Sex and Circadian Rhythm. <i>Nuklearmedizin - NuclearMedicine</i> , 2018, 57, 224-233.	0.7	4
16	Normal Values of Thyroid Uptake of 99mTechnetium Perchnetate SPECT in Mice with Respect to Age, Sex, and Circadian Rhythm. <i>Nuklearmedizin - NuclearMedicine</i> , 2018, 57, 181-189.	0.7	7
17	Performance Evaluation of Stationary and Semi-Stationary Acquisition with a Non-Stationary Small Animal Multi-Pinhole SPECT System. <i>Molecular Imaging and Biology</i> , 2014, 16, 311-316.	2.6	16